All News #Library
Biotech
IDEAYA, Hengrui to Present IDE849 (SHR-4849) Data at IASLC 2025
22 Jul 2025 //
PR NEWSWIRE
Hengrui`s Camrelizumab Combo Doubles 5-Year Survival in Lung Cancer
01 Apr 2025 //
PR NEWSWIRE
IDEAYA Biosciences Licenses SHR-4849 ADC for SCLC and NET Tumors
29 Dec 2024 //
PR NEWSWIRE

Market Place
Sourcing Support